Cidara Therapeutics, Inc. Stock price

Equities

CDTX

US1717571079

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2023-12-01 pm EST Intraday chart for Cidara Therapeutics, Inc. 5-day change 1st Jan Change
0.7809 USD +10.08% +9.99% +3.25%
Sales 2023 * 57.85 M Sales 2024 * 21.07 M Capitalization 70.62 M
Net income 2023 * -27.00 M Net income 2024 * -56.00 M EV / Sales 2023 *
1,22x
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 *
3,35x
P/E ratio 2023 *
-2,55x
P/E ratio 2024 *
-1,35x
Employees 73
Yield 2023 *
-
Yield 2024 *
-
Free-Float 92.68%
More Fundamentals * Assessed data
Dynamic Chart
Earnings Flash (CDTX) CIDARA THERAPEUTICS Posts Q3 Revenue $12.7M MT
Cidara Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Cidara Therapeutics and Mundipharma Receive Positive CHMP Opinion for Rezafungin for the Treatment of Invasive Candidiasis in Adults CI
Cidara Therapeutics, Inc. Presents New Preclinical and Clinical Data on Novel Drug-Fc Conjugate CD388 at IDWeek 2023 CI
Transcript : Cidara Therapeutics, Inc. - Special Call CI
Cidara Shares Rally Premarket as J&J Moves Forward on Influenza Pact DJ
Cidara Therapeutics, Inc. Announces Janssen?S Election to Proceed Under Its License Agreement Relating to Novel Drug-Fc Conjugates Targeting Influenza CI
Cidara Therapeutics, Inc. Appoints Nicole Davarpanah as Senior Vice President of Translational Research and Development CI
Earnings Flash (CDTX) CIDARA THERAPEUTICS Posts Q2 Revenue $7.6M MT
Cidara Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Cidara Therapeutics Says Partner Melinta Therapeutics Launched Candidemia Treatment Rezzayo in US MT
Cidara Therapeutics Provides Update on REZZAYO? (Rezafungin for Injection) CI
Cidara Therapeutics, Inc.(NasdaqCM:CDTX) added to Russell 3000E Growth Index CI
Cidara Therapeutics, Inc.(NasdaqCM:CDTX) added to Russell Microcap Value Index CI
Cidara Therapeutics, Inc.(NasdaqCM:CDTX) added to Russell 3000E Value Index CI
More news
1 day+10.08%
1 week+9.99%
Current month+10.08%
1 month-2.81%
3 months-1.15%
6 months-40.84%
Current year+3.25%
More quotes
1 week
0.68
Extreme 0.68
0.79
1 month
0.59
Extreme 0.593
0.91
Current year
0.59
Extreme 0.593
2.10
1 year
0.46
Extreme 0.4601
2.10
3 years
0.40
Extreme 0.4
3.15
5 years
0.40
Extreme 0.4
4.45
10 years
0.40
Extreme 0.4
19.13
More quotes
Managers TitleAgeSince
Chief Executive Officer 68 2013
Director of Finance/CFO 50 2021
Chief Tech/Sci/R&D Officer 56 2012
Members of the board TitleAgeSince
Chairman 61 2014
Director/Board Member 68 2014
Chief Executive Officer 68 2013
More insiders
Date Price Change Volume
23-12-01 0.7809 +10.08% 531,867
23-11-30 0.7094 +2.66% 295,846
23-11-29 0.6910 +1.32% 255,396
23-11-28 0.6820 -3.00% 386,448
23-11-27 0.7031 -0.97% 283,997

Delayed Quote Nasdaq, December 01, 2023 at 04:00 pm EST

More quotes
Cidara Therapeutics, Inc. is a biotechnology company. The Company is focused on the discovery, development and commercialization of therapeutics designed for patients facing serious diseases. The Company's lead product candidate is rezafungin acetate, an intravenous formulation of an echinocandin. Rezafungin is being developed as a once-weekly, high-exposure therapy for the treatment and prevention of serious invasive fungal infections. The Company's primary focus is using its Cloudbreak platform to develop a potential new class of drugs called drug-Fc conjugates (DFCs), for the prevention and treatment of serious diseases. This technology couples? potent inhibitors to a human antibody fragment to create long-acting DFCs designed to inhibit multiple disease targets. Its advanced DFC program is CD388, a long-acting antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase I and Phase IIa clinical trials.
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.7809USD
Average target price
4.667USD
Spread / Average Target
+497.60%
Consensus
1st Jan change Capi.
+3.25% 71 M $
+21.60% 90 488 M $
+12.94% 86 658 M $
+2.47% 34 551 M $
+19.81% 26 777 M $
-33.83% 23 629 M $
-26.62% 20 547 M $
-14.75% 19 529 M $
-1.94% 11 507 M $
+20.17% 10 906 M $
Bio Therapeutic Drugs
  1. Stock
  2. Equities
  3. Stock Cidara Therapeutics, Inc. - Nasdaq
As early as today, start finding the best investment opportunities!
Optimize my profits
fermer